军事知识服务平台
卡度尼利单抗联合贝伐珠单抗类似物与化疗治疗转移性结直肠癌的疗效评价及生存质量分析
Efficacy evaluation and quality of life analysis of cadonilimab combined with bevacizumab biosimilar and chemotherapy in the treatment of metastatic colorectal cancer
摘要 目的 探索卡度尼利单抗联合贝伐珠单抗类似物和化疗(FOLFOX/FOLFIRI)一线治疗RAS突变、微卫星稳定(MSS)型转移性结直肠癌(mCRC)的疗效与安全性.方法 采用前瞻性单臂探索性研究方法,选择2024年4月—2025年4月就诊于内蒙古自治区人民医院的RAS突变、MSS型mCRC患者为研究对象,接受卡度尼利单抗250 mg+贝伐珠单抗5~7.5 mg/kg+FOLFOX/FOLFIRI方案化疗.主要研究终点为无进展生存期(PFS),次要研究终点为客观缓解率(ORR)、疾病控制率(DCR),以及3、6、12个月PFS率和不良反应发生率等.同时根据欧洲癌症研究与治疗组织生命质量核心(EORTC QLQ-C30)量表评估患者治疗前后的生活质量.结果 共纳入32例患者,治疗后ORR为53.1%,DCR达96.9%.中位PFS为11.4个月,95%置信区间(CI)(9.6,13.5)个月,中位总生存期尚未达到,3、6、12个月的PFS率分别为96.9%、90.6%、46.9%.治疗后常见的不良反应包括骨髓抑制、呕吐/恶心、手足综合征及内分泌毒性.大多数不良反应为1~2级,少数为3级,未发生4~5级不良反应.亚组分析显示,东部肿瘤协作组(ECOG)评分≥2分、原发癌部位为右半结肠、合并肝转移的患者预后显著更差(P<0.05).EORTC QLQ-C30量表评估显示,患者总体健康状况及功能领域显著改善,核心症状明显缓解.结论 在RAS突变、MSS型mCRC一线治疗中,卡度尼利单抗联合贝伐珠单抗类似物及化疗的治疗方案在ORR、PFS等关键疗效终点上呈现出一定获益,且整体安全性可控,未出现新的、不可耐受的毒性反应,且对于ECOG评分在0~1分、原发癌部位为左半结肠以及无肝转移的患者更有优势.由于纳入样本量较少、随访时间短等局限性,后续需要开展大型临床研究进一步探索验证.
Abstract:
Objective To explore the efficacy and safety of cadonilimab combined with bevacizumab biosimilar and chemotherapy(FOLFOX/FOLFIRI)as first-line treatment for RAS-mutated,microsatellite stable(MSS)metastatic colorectal cancer(mCRC).Methods Using a prospective,single-arm exploratory study,patients with RAS-mutated,MSS mCRC who visited the People's Hospital of Inner Mongolia Autonomous Region from April 2024 to April 2025 were selected.They received chemotherapy with 250 mg of cadonilimab plus 5-7.5 mg/kg of bevacizumab and FOLFOX/FOLFIRI regimens.The primary endpoint was progression-free survival(PFS),and the secondary endpoints were objective response rate(ORR),disease control rate(DCR),as well as PFS rates at 3,6,and 12 months and the incidence of adverse reactions.Additionally,the quality of life of patients before and after treatment was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)scale.Results A total of 32 patients were enrolled,with an ORR of 53.1%and a DCR of 96.9%after treatment.The median PFS was 11.4 months,with a 95%confidence interval(CI)of(9.6,13.5)months.The median overall survival was not reached.The PFS rates at 3,6,and 12 months were 96.9%,90.6%,and 46.9%,respectively.Common adverse reactions after treatment included myelosuppression,vomiting/nausea,hand-foot syndrome,and endocrine toxicity.Most adverse reactions were grade 1 to 2,with a few being grade 3.No grade 4 to 5 adverse reactions occurred.Subgroup analysis showed that patients with an Eastern Cooperative Oncology Group(ECOG)score≥2,primary cancer site in the right-sided colon,and concurrent liver metastasis had significantly poorer prognosis(P<0.05).The EORTC QLQ-C30 scale assessment showed improvements in patients'overall health status and functional domains,with core symptoms significantly alleviated.Conclusion In the first-line treatment of RAS-mutated,MSS mCRC,the treatment regimen combining cadonilimab with bevacizumab analogues and chemotherapy showed certain benefits in key efficacy endpoints such as ORR and PFS,with manageable overall safety.No new or intolerable toxicities were observed,and it has advantages for patients with ECOG scores of 0-1,with a primary tumor in the left-sided colon,and without liver metastasis.Due to limitations such as a small sample size and short follow-up time,large-scale clinical studies should be conducted in the future for further exploration and verification.
刊 名 药学前沿
年,卷(期): 2026, 30(9)
分类号: R979
机标分类号: R737.33 R181.37 R285.6
在线出版日期: 2026年10月16日
基金项目: 2022MS08075:内蒙古自治区自然科学基金项目2022YFSH0097:内蒙古自治区科技计划项目:内蒙古自治区医师协会临床医学研究YSXH2024KYD04:临床新技术推广项目,